Burning Rock Biotech Stock Scheduled to Reverse Split on Wednesday, May 15th (NASDAQ:BNR)

Burning Rock Biotech Limited (NASDAQ:BNR) shares are set to reverse split on Wednesday, May 15th. The 1-10 reverse split was announced on Wednesday, May 15th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, May 15th.

Burning Rock Biotech Price Performance

Shares of NASDAQ:BNR opened at $0.81 on Tuesday. The business’s fifty day moving average price is $0.77 and its two-hundred day moving average price is $0.85. Burning Rock Biotech has a fifty-two week low of $0.57 and a fifty-two week high of $3.04. The stock has a market capitalization of $83.14 million, a price-to-earnings ratio of -0.91 and a beta of 0.18.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.22) earnings per share for the quarter. Burning Rock Biotech had a negative net margin of 121.79% and a negative return on equity of 71.77%. The company had revenue of $17.05 million during the quarter.

Institutional Trading of Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Lansdowne Partners UK LLP bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 122,593 shares of the company’s stock, valued at approximately $119,000. Lansdowne Partners UK LLP owned about 0.12% of Burning Rock Biotech as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.